China Pharma (NYSE:CPHI) Trading Down 4.5% – Should You Sell?

China Pharma Holdings, Inc. (NYSE:CPHI)’s share price was down 4.5% on Wednesday . The company traded as low as $0.5222 and last traded at $0.5274. Approximately 20,409 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 42,967 shares. The stock had previously closed at $0.5522.

China Pharma Price Performance

The company has a current ratio of 0.79, a quick ratio of 0.26 and a debt-to-equity ratio of 0.22. The stock has a market cap of $21.37 million, a price-to-earnings ratio of -0.70 and a beta of 0.99. The stock has a 50-day moving average price of $0.60 and a two-hundred day moving average price of $1.08.

Institutional Trading of China Pharma

A hedge fund recently raised its stake in China Pharma stock. Citadel Advisors LLC grew its stake in China Pharma Holdings, Inc. (NYSE:CPHI) by 31.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 30,426 shares of the company’s stock after buying an additional 7,356 shares during the quarter. Citadel Advisors LLC owned 0.93% of China Pharma worth $59,000 as of its most recent SEC filing.

About China Pharma

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.